Roflumilast reduces the number of lung adenocarcinomas, inflammation, and emphysema in a smoking-induced mouse model
This study highlights the potential use of roflumilast as a chemopreventive agent for patients with chronic obstructive pulmonary disease who are at risk of lung cancer and underscores its relevance for future clinical application and research on phosphodiesterase-4 inhibitors.
Authors
- Naofumi Kameyama (ORCID: https://orcid.org/0000-0002-7920-3948)
- Ahmed E. Hegab (ORCID: https://orcid.org/0000-0002-5432-7506)
- Hideki Terai (ORCID: https://orcid.org/0000-0002-1118-1930)
- Masayuki Shimoda (ORCID: https://orcid.org/0000-0003-4929-6546)
- H. Irie (ORCID: https://orcid.org/0000-0001-7973-1006)
- Koichi Fukunaga (ORCID: https://orcid.org/0000-0001-7460-1990)
- Shingo Nakayama (ORCID: https://orcid.org/0000-0003-1009-9860)
- Yae Kanai (ORCID: https://orcid.org/0000-0002-7904-9506)
- Hiroyuki Yasuda (ORCID: https://orcid.org/0000-0001-9966-8569)
- Shotaro Chubachi (ORCID: https://orcid.org/0000-0002-5046-3762)
- Takashi Shimada (ORCID: https://orcid.org/0000-0003-3299-1630)
- Kaori Sakurai (ORCID: https://orcid.org/0000-0002-1565-781X)
- Junko Hamamoto (ORCID: https://orcid.org/0000-0002-4512-4221)
- Akihiro Tsutsumi
- Shiro Otake
Institutions
- Jikei University School of Medicine (JP)
- Keio University (JP)
- Keio University Hospital (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1186/s12890-025-03730-w
- Citations
- 2
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Keio University
- Japan Society for the Promotion of Science